Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Featured News 2 Small-Cap Biotechs That Could Reward Patient InvestorsWritten by Chris Markoch. Published 12/12/2025. 
Key Points - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investing and patience rarely go hand in hand. Nevertheless, if you’re looking to invest in the small-cap biotech sector, patience is a requirement. Most of these companies are still in the clinical stage, meaning they have no commercially available drugs or therapeutics. They therefore have negative earnings (not profitable) and little to no revenue. Success often hinges on the outcome of a single clinical-stage drug or therapeutic. Trade /-3X leverage on Gold Miners.
§SHNY
$DULL
3XGold
Exchange Traded Notes
Learn More Learn More Even if a product advances through trials, profitability may still be years away. Only after achieving commercial success do companies typically attract analyst coverage and institutional investment. However, investing early in one of these medical stocks that succeeds can produce outsized gains. In a short period, investors might see 3x, 5x, or even 10x returns. Others may never pan out. That’s why some penny-stock investors spread their capital across many biotech firms—if it’s a numbers game, diversification can help manage risk. With that in mind, let’s examine two small-cap biotech stocks that carry significant risks but also the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company that specializes in epigenetics-based tests for the early detection of cancer. Unlike some penny stocks in this space, Mainz Biomed has a commercially available product: ColoAlert—the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, one of Germany’s digital-health pioneers. With more than 60,000 new colorectal cancer cases annually in Germany, the market opportunity is meaningful. Mainz Biomed is also in the early stages of developing a non-invasive blood-based screening test for early detection of pancreatic cancer. The company reported positive topline results in October, though any commercial approval is still years away. But risks remain substantial. ColoAlert is not yet available in the United States, and even with early sales in Europe and plans to expand into South America, revenue is currently minimal. The company included “Going Concern” language in its Sept. 26 SEC filing. Since then, Mainz Biomed filed a $150 million mixed-shelf offering. That financing has helped keep MYNZ above $1 and avoid delisting for now. The company is racing to generate enough revenue to move the needle. If it succeeds, even a relatively small investment could yield a sizable return. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is another micro-cap biotech that offers a potentially disruptive approach to antiviral treatment—but it also carries significant financial risk that speculative investors must weigh carefully. The company is developing a novel class of antiviral therapies based on its proprietary “nanoviricide” platform. These candidates are designed to mimic human cell surfaces to lure viruses into binding with them, neutralizing pathogens before they can infect real cells. If validated in human trials, this approach could represent a new modality in infectious disease treatment. NanoViricides’ pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced and has shown encouraging preclinical antiviral activity. Like many micro-cap biotechs, NanoViricides remains pre-revenue and reliant on fresh capital to advance its programs. Recent filings show limited cash on hand, so investors should expect the possibility of future dilution. Still, if one candidate advances successfully into clinical development, the valuation upside could be substantial. For patient investors with a high tolerance for risk, NNVC represents a genuine moonshot in the antiviral space.
| 
